Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $15.6 billion and adjusted earnings of $1.72 per ...

Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our Earnings Yield Investor model based on the published strategy ...

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other dividend stocks. The Dow is a highly recognized and influential stock market index that ...

MRK has a good track record of advancing its pipeline to address unmet patient needs, and all the while, produce solid shareholder returns. To reinforce this idea, Leo Nelissen points out in his ...

Merck (MRK) stock is sinking 10% after the company provided weaker-than-expected 2025 guidance amid weak sales of Gardasil, its HPV vaccine. Additionally, the huge drug maker withdrew its long-ter ...

Merck (MRK) stock was mangled today after the pharmaceutical and vaccine company released its guidance for 2025. The company expects adjusted earnings per share for the year to range from $8.88 to ...

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

In a report released today, Chris Schott from J.P. Morgan maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $130.00. The company’s shares closed ...

Over the past ten years, MRK has bought back roughly 11% of its shares and hiked its dividend by 80%. Data by YCharts Currently yielding 3.3%, the dividend has a payout ratio in the low 50% range ...